Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence.
Heart failure (HF) is a growing health concern in aging societies worldwide. Sacubitril/valsartan is changing the real-world treatment in the whole spectrum of HF. The beginning was the PARADIGM-HF trial published in 2014, which demonstrated the beneficial effects of inhibiting natriuretic peptide breakdown in combination with hindering the renin-angiotensin system in HF patients with a reduced ejection fraction. Subsequent large-scale randomized trials have evaluated angiotensin receptor-neprilysin inhibitor in HF patients with acute decompensation or with preserved ejection fraction. The post hoc analyses are being conducted as well. This review summarizes the recent evidence of sacubitril/ valsartan regarding patient-centered outcomes, based on randomized controlled trials and their associated studies.
['Choi|Hong-Mi|HM|', 'Shin|Mi-Seung|MS|']
D057911:Angiotensin Receptor Antagonists D000959:Antihypertensive Agents D006333:Heart Failure D006801:Humans D015260:Neprilysin D011945:Receptors, Angiotensin
Heart failure Angiotensin receptor inhibitor Neprilysin